

555, 757

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
25 November 2004 (25.11.2004)

PCT

(10) International Publication Number
WO 2004/100943 A1

(51) International Patent Classification⁷: **A61K 31/231**,
31/232, 35/78, 35/84, A61P 25/28

(21) International Application Number:
PCT/GB2004/002089

(22) International Filing Date: 14 May 2004 (14.05.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0311081.4 14 May 2003 (14.05.2003) GB
60/497,332 25 August 2003 (25.08.2003) US

(71) Applicant (for all designated States except US): **BTG INTERNATIONAL LIMITED** [GB/GB]; 10 Fleet Place, Limeburner Place, London EC4M 7SB (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **HARBIGE, Laurence, S.** [GB/GB]; 40 Middleton Close, London E4 8EA (GB). **LEACH, Michael, J.** [GB/GB]; 48 Cherry Tree Walk, West Wickham, Kent BR4 9EF (GB). **SHARIEF, Mohammed** [GB/GB]; Dept. of Clinical Neurosciences, Guy's, King's & St Thomas' School of Medicine, Hodgkin Building, Guy's Hospital, London SE1 9RT (GB).

(74) Agent: **DOLAN, Anthony, Patrick**; 10 Fleet Place, Limeburner Lane, London EC4M 7SB (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **USE OF TRIGLYCERIDE OILS CONTAINING GAMMA-LINOLENIC ACID RESIDUES AND LINOLEIC ACID RESIDUES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASE**

(57) Abstract: A method is provided for treating a patient in need of therapy for a neurodegenerative disease comprising administering to that patient a therapeutically effective dose of a triglyceride oil containing both γ -linolenic acid and linoleic acid residues as triglyceride ester, the ratio of γ -linolenic acid to linoleic acid residues at the sn-2 position of the triglyceride being at least 0.8; the amount of γ -linolenic acid residues at the sn-2 position being at least 18 %, wherein the oil is administered at a dose sufficient to maintain or elevate TGF- β 1 levels in the patient at a therapeutic level. Preferably the method is that wherein the therapeutic level is such as to produce a TGF- β 1/TNF- α ratio of at least 0.5 in blood of a patient, after 18 months of daily dosing. Preferred oils are Borage or Mucor oils having at least 35 % of the sn-2 position fatty acid residues as γ -linolenic acid.



WO 2004/100943 A1